First Horizon Advisors’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-230
Closed -$2.33K 2312
2023
Q4
$2.33K Hold
230
﹤0.01% 1987
2023
Q3
$1.79K Hold
230
﹤0.01% 2016
2023
Q2
$1.89K Hold
230
﹤0.01% 2094
2023
Q1
$1.67K Hold
230
﹤0.01% 2147
2022
Q4
$2.04K Sell
230
-243
-51% -$2.67K ﹤0.01% 2060
2022
Q3
$5K Sell
473
-8
-2% -$125 ﹤0.01% 1758
2022
Q2
$5K Buy
+481
New +$6.45K ﹤0.01% 1821
2022
Q1
Sell
-765
Closed -$19K 1860
2021
Q4
$19K Sell
765
-428
-36% -$14.7K ﹤0.01% 1295
2021
Q3
$48K Buy
1,193
+435
+57% +$23.8K ﹤0.01% 918
2021
Q2
$42K Buy
758
+269
+55% +$9.94K ﹤0.01% 845
2021
Q1
$20K Buy
+489
New +$27.9K ﹤0.01% 1071
2020
Q3
Sell
-550
Closed -$16K 1456
2020
Q2
$16K Hold
550
﹤0.01% 868
2020
Q1
$11K Hold
550
﹤0.01% 912
2019
Q4
$16K Buy
+550
New +$13.7K ﹤0.01% 934

Other funds holding EDIT

First Horizon Advisors's EDIT Position: Q1 2024 in Review

First Horizon Advisors sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 230 shares — an estimated $2.33K sold.

First Horizon Advisors first reported a position in EDIT in Q4 2019 and held it in 14 quarters. The position peaked at $48K in Q3 2021. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

  • First Horizon Advisors reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
  • First Horizon Advisors sold 230 Editas Medicine shares in Q1 2024, an estimated $2.33K.
  • First Horizon Advisors first reported a position in Editas Medicine in Q4 2019 and held it in 14 quarters.
  • First Horizon Advisors's Editas Medicine position peaked at $48K in Q3 2021.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on First Horizon Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.